Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 5871  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed10526    
    Printed253    
    Emailed6    
    PDF Downloaded482    
    Comments [Add]    
    Cited by others 3    

Recommend this journal

 

 ORIGINAL ARTICLE
Year : 2009  |  Volume : 57  |  Issue : 3  |  Page : 295--299

Once daily baclofen sustained release or gastro-retentive system are acceptable alternatives to thrice daily baclofen immediate release at same daily dosage in patients


1 Breach Candy Hospital, Matru Mandir, 278 Tardeo Road, Mumbai - 400 007, India
2 Department of Neurology, Dinanath Mangeshkar Hospital and Research Center, Pune - 411 004, India
3 Department of Neurology, Wanless Hospital, Miraj - 416 410, India
4 Sheth V. S. General Hospital, Aarsi Corner, Ellisbridge, Ahmedabad - 380 006, India
5 B. J. Medical College, Ahmedabad - 382 443, India
6 Government Medical College, Surat- 395 001, India
7 Department of Medicine, Pramukhswami Medical College, Karamsad - 388 325, India
8 Clinical Research, Sun Pharma Ltd., Mumbai - 400 093, India

Correspondence Address:
Shravanti S Bhowmik
C-11, Symphony CHS Ltd., Chandivili, Powai, Mumbai - 400 072
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.53284

Rights and Permissions

Background: Baclofen, a GABA-agonist, is currently available as an immediate release (IR) formulation for relieving neurogenic spasticity in a variety of disorders. Baclofen IR requires to be administered three times a day which inadvertently increases the chances of medication noncompliance among patients and is also associated with side effects such as drowsiness and muscle weakness. Aim: To overcome the shortcomings of baclofen IR, two modified formulations, baclofen sustained release (SR) and gastric retentive system (GRS), have been proposed to be equivalent in efficacy to baclofen IR with the administration of a single daily dose. Materials and Methods: Ninety patients with chronic neurogenic muscular spasticity were enrolled requiring 10-20 mg of baclofen IR every eight hours. The patients were randomized to two treatment arms: SR (n = 46) or GRS (n = 44) at the same once-daily dose for four weeks. Efficacy was measured by Ashworth score for muscle tone, spasm score, reflex score, 30-item functional independence score, and patient's diary score for three most affected activities of daily life. Results: The mean Ashworth score changed significantly (P = 0.00) for patients in the SR group from 3.03-2.69 (-0.35) and 3.07-2.70 (-0.37) for patients in the GRS group. There was no significant difference (P = 0.87) between baseline-adjusted Ashworth score reductions on SR (-0.35) and GRS (-0.37). Similar results were obtained for spasm, reflex, and functional independence scores. The mean baseline-adjusted patient-diary scores did not differ significantly between 8 am, 12 pm, 4 pm, and 8 pm (P = 0.96), either on SR (-5.3 to -6.1) or GRS (-7.3 to -8.1), indicating a uniform effect round-the-day on both. Further, sedation scores (mean ± SEM) decreased significantly (P < 0.05) on both SR (10.36 ± 1.37 to 6.18 ± 0.92) and GRS (8.14 ± 1.57 to 5.33 ± 1.11), suggesting better toleration. Conclusion: Once-daily baclofen SR and GRS are efficacious, convenient, and better-tolerated alternatives to baclofen IR in patients with neurogenic spasticity.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow